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CHAPTER 1. INTRODUCTION  
Stroke is a major public health problem and cause of death. The majority of 
strokes are ischemic strokes that represent 80-90% of all strokes.1 
Ischemic strokes often result in devastating and irreversible conditions and 
survivors of ischemic strokes may experience mental and physical impairment 
diminishing quality of life. Ischemic strokes place a substantial burden on 
families and health care systems and give rise to large societal costs.2 
Moreover, ischemic stroke increases with advancing age and the impact of 
ischemic stroke is expected to increase as the proportion of the aged 
population increases. In 2010, the global incidence of ischemic stroke was 
approximately 11.6 million events with almost 70% occurring in individuals 
>65 years of age.1 
Almost 80% of ischemic strokes are first time diagnoses emphasizing the 
importance of primary prevention. Lifestyle and diet are the cornerstones of 
prevention and has the advantage that it is generally cheap and can be applied 
to whole populations and further adds to improvement of other health aspects. 
A key component of a healthy dietary pattern may be the intake of 
polyunsaturated fatty acids (PUFA). 
This PhD thesis aimed to examine the association between long-term dietary 
intake of n-6 and marine n-3 PUFA and the risk of ischemic stroke and its 
subtypes. The thesis is based on four studies using data from the Diet, Cancer 
and Health cohort, which is a prospective cohort study of 57,053 Danish men 
and women.
CHAPTER 2. BACKGROUND 
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CHAPTER 2. BACKGROUND 
ISCHEMIC STROKE 
Stroke is a major cause of death and long-term disability worldwide.1 There 
are two main types of stroke; ischemic stroke and hemorrhagic stroke. These 
two types of strokes have entirely different etiology. Hemorrhagic stroke 
occurs when a blood vessel in the brain ruptures with subsequent bleeding 
into the brain. Ischemic stroke is caused by a blockage of an artery that 
supplies the brain resulting in inadequate supply of oxygen to the brain. 
Ischemic strokes accounts for 80-90% of all strokes in Western countries.1  
Ischemic stroke is a heterogenous condition and can be divided into 5 
subgroups according to the Trial of Org 10172 in Acute Stroke Treatment 
(TOAST) classification system,3 which is a system based on etiology (Table 
1). 
Table 1: Subtypes of the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification 
system.  
Subtype Diagnosis Cause 
Large artery 
atherosclerosis 
>50 % stenosis or occlusion of a major brain 
artery or branch cortical artery of 
atherosclerotic origin. 
Mainly due to 
atherosclerosis.3 
Cardioembolism Arterial occlusion due to an embolus arising in 
the heart and at least one cardiac source for 
an embolus must be identified 
Mainly due to atrial 
fibrillation/atrial 
flutter.4 
Small-vessel 
occlusion 
Occlusion of small penetrating arteries 
providing blood to the deep structures of the 
brain. Large artery and cardiac sources must 
be excluded. The diagnosis is supported by a 
history of diabetes mellitus or hypertension. 
Mainly due to 
lipohyalinosis or 
atherosclerosis.5 
Stroke of other 
etiology 
Clinical and CT or MRI findings of an ischemic 
stroke but blood tests or arteriography reveals 
a rare cause. 
Strokes due to rare 
causes including: 
nonatherosclerotic 
vasculopathies, 
hypercoagulable 
states or 
hematologic 
disorders.3 
Stroke of 
undetermined 
etiology 
Ischemic stroke cases with incomplete 
evaluations or two or more potential causes. 
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While ischemic strokes are of heterogenous origin, atherosclerosis is a 
common pathophysiological background behind many ischemic strokes. 
Atherosclerosis is a very complex process that occurs within the arterial wall 
due to a multifactorial life-long process, where lipids, inflammatory and 
hemostatic mediators lead to plaque formation.6–9 The diameter of the artery 
shrinks with subsequent decrease of the blood flow resulting in reduced 
oxygen supply. Plaque rupture may lead to acute complications of 
atherosclerosis such as coronary heart disease (CHD) or ischemic stroke.10,11 
Ischemic stroke can also occur due to vessel occlusion by growth of a stable 
plaque, however, studies suggest that the predominant mechanism involves 
plaque rupture.12–14 
Well established risk factors of ischemic stroke include age, sex, 
anthropometry, smoking, physical activity and alcohol intake.1,2,15 
Furthermore, some but not all studies have found an association between 
plasma cholesterol and risk of ischemic stroke.16–21 Regarding lipids 
associations have mainly been attributed to plasma levels of low-density 
lipoprotein (LDL)-cholesterol and a meta-analysis of 14 randomized controlled 
trials found a lower risk of ischemic stroke when LDL-cholesterol was 
reduced.22 The larger cerebral arteries may be more susceptible to LDL-
cholesterol exposure, and therefore, LDL-cholesterol may be stronger 
associated with strokes due to large artery atherosclerosis.23 Furthermore, 
plasma triglyceride levels may also be associated with ischemic stroke risk.1,24 
Hypertension is the main risk factor for hemorrhagic stroke but is also a major 
risk factor of ischemic stroke and the risk increases progressively with 
increasing blood pressure.15,25 Hence, randomized controlled trials have found 
a lower risk of stroke with reduction of blood pressure.26,27  
Prospective cohort studies have reported positive associations between 
occurrence of diabetes mellitus and risk of ischemic stroke.28 Subjects with 
diabetes mellitus are more prone to develop atherosclerosis and the 
prevalence of hypertension and hypercholesterolemia is increased in people 
with diabetes.2  
Atrial fibrillation/atrial flutter is another important risk factor of ischemic stroke 
especially strokes due to cardioembolism.29 Thus, studies have shown that 
chronic atrial fibrillation is associated with more than a fivefold higher risk of 
stroke.30  
Diet may also influence the risk of ischemic stroke. In particular, some fatty 
acids from the diet may have detrimental effects on blood lipids, blood 
pressure, insulin sensitivity, arrhythmias, platelet aggregability, endothelial 
function and inflammation.31–33 
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FATTY ACIDS 
Fatty acids can be classified as saturated fatty acids (SFA), monounsaturated 
fatty acids (MUFA) or PUFA according to the number of double bonds (Figure 
1). SFA lack double bonds, MUFA have one double bond whereas PUFA 
contain two or more double bonds (Figure 2).34 SFA composes around 14 % 
energy of the average Danish dietary intake with butter, meat, sweet bakery 
products, confectionary and dairy products as the main sources.35,36  MUFA is 
presented in several food groups and contributes with 13 % energy of the 
dietary intake.35,36 The average Danish dietary intake of PUFA is 5.6 % energy 
and the main sources are soft margarines and vegetable oils.35,36 
 
Figure 1: Types of major dietary fatty acids. SFA indicates saturated fatty acids; MUFA, 
monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; LA, linoleic acid; ALA, 
alpha-linolenic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, 
docosahexaenoic acid. 
PUFA from the diet can be divided into n-3 and n-6 PUFA. Counted from the 
methyl end, n-3 and n-6 have their first double bond in the n-3 position and n-
6 position, respectively.  
N-3 AND N-6 PUFA AND ISCHEMIC STROKE 
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Figure 2: Classification of major fatty acids.  
 
N-3 PUFA can be divided into plant-derived n-3 PUFA, namely alpha-linolenic 
acid (ALA) and marine n-3 PUFA, such as eicosapentaenoic acid (EPA), 
docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA).   
ALA can to a limited extent in humans be converted through a pathway 
involving desaturation to form stearidonic acid, and elongation to form 
eicosatetraenoic acid and further desaturation to form EPA (Figure 3). EPA 
can further undergo elongation, desaturation and oxidation to form DPA and 
DHA.37–39 The main source of marine n-3 PUFA is seafood, especially fatty 
fish. The most widely consumed n-6 PUFA is linoleic acid (LA), which is 
derived from many different sources, although, vegetable oils is the primary 
source.40–42 After consumption, LA can be converted to other n-6 PUFA by 
CHAPTER 2. BACKGROUND 
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steps similar to the conversion of ALA (Figure 3). LA is first desaturated to 
form gamma-linoleic acid, and elongated to form di-homo-gamma-linoleic acid 
and further desaturated to form arachidonic acid (AA).43 AA can also be 
consumed in the diet with the most important dietary sources being eggs and 
meat.44 LA and ALA are essential since they cannot be synthesized by the 
human body and must be provided in the diet.   
 
Figure 3: Pathway of the conversion of LA to AA and ALA to DHA. LA indicates linoleic acid; 
AA, arachidonic acid; ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; DPA, 
docosapentaenoic acid; DHA, docosahexaenoic acid.  
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N-3 and n-6 PUFA are incorporated into cells and tissues where they are 
stored and can be metabolized into biologically active and less active 
compounds. Thus, AA and EPA are incorporated into platelets and leucocytes 
from where they can be further metabolized into thromboxanes and 
leukotrienes, respectively.43 Because AA can be converted to the 
proaggregatory and vasoconstrictive thromboxane A2 in platelets and 
proinflammatory leukotrienes B4 in leucocytes, it has been suggested that 
excessive LA intake could lead to increased thrombotic risk or inflammation 
and thereby to atherosclerotic diseases. EPA, however, is converted to the 
less proaggregatory thromboxane A3 and less proinflammatory leukotriene 
B5 suggesting beneficial effects of marine n-3 PUFA with respect to 
atherosclerosis and vascular diseases. Because of competition for the same 
enzymes it has been suggested that LA intake should be decreased while 
intake of EPA and DHA should be increased to reduce vascular disease.45,46 
However, because AA levels are under close homeostatic regulations, dietary 
intake of LA may not be correlated with levels of AA in plasma or adipose 
tissue.43,47–49 
Marine n-3 PUFA have been associated with beneficial effects on blood 
pressure, plasma triglycerides, platelet aggregability and inflammatory 
measures.39,50,51 LA has primarily been associated with a lowering of LDL-
cholesterol, but LA may also lower blood pressure and improve insulin 
sensitivity.52,53 Both LA and marine n-3 PUFA have shown inverse 
associations with CHD.54,55 Though both CHD and ischemic stroke have 
atherosclerotic etiology, and despite beneficial associations with risk factors 
of ischemic stroke, prospective cohort studies of long-term intake of LA and 
marine n-3 PUFA in relation to ischemic stroke incidence have shown 
inconsistent results. 
LA is being consumed in large quantities and contribute considerably to the 
total energy intake. Hence, if energy balance is maintained, a higher intake of 
LA must necessarily be accompanied by a lower intake of other 
macronutrients such as SFA, MUFA or glycemic carbohydrates. Similarly, 
intake of fish should be investigated as replacements of other food items.  
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CHAPTER 3. AIMS AND HYPOTHESES 
The overall aim of this PhD thesis was to examine the association between 
long-term dietary intake of the n-6 PUFA LA and total marine n-3 PUFA, EPA 
and DHA and the risk of ischemic stroke and its subtypes. 
The specific aims and hypotheses in this thesis were:  
Study I 
The aim of the first study was to investigate the hypothesis that a higher intake 
of LA and a concomitant lower intake of SFA, MUFA or glycemic carbohydrate 
was associated with a lower risk of ischemic stroke and its subtypes. 
 
Study II 
The aim of the second study was to investigate the hypothesis that adipose 
tissue content of LA was inversely associated with the risk of ischemic stroke 
and its subtypes. 
 
Study III 
The aim of the third study was to investigate the hypothesis that intake and 
content in adipose tissue of total marine n-3 PUFA, EPA and DHA were 
inversely associated with the risk of ischemic stroke and its subtypes. 
 
Study IV 
The aim of the fourth study was to investigate the hypothesis that a higher 
intake of fish and a concomitant lower intake of red meat or poultry was 
associated with a lower risk of ischemic stroke and its subtypes. 
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CHAPTER 4. METHODS 
STUDY POPULATION 
This thesis was based on data from the Danish Diet, Cancer and Health cohort 
study, which was originally established to investigate the role of diet and 
lifestyle in relation to incident cancer and other chronic diseases.56 The study 
was initiated from December 1993 to May 1997 by inviting 160,725 men and 
women by mail. Non-responders received a second letter. A total of 57,053 
men and women accepted the invitation corresponding to 35% of those 
invited. All participants were between 50-64 years old, citizens of the greater 
Copenhagen or Aarhus areas and not previously registered in the Danish 
Cancer Registry. All participants gave written informed consent at inclusion, 
and the study was approved by the relevant ethics committees and the Danish 
Data Protection Agency. A subcohort of 3500 participants was randomly 
drawn from the whole cohort. Participants with stroke or cancer or missing 
information on potential confounders before recruitment were excluded.   
 
ASSESSMENT OF DIETARY INTAKE 
At baseline participants filled in a validated semiquantitative food frequency 
questionnaire which included 192 food and drink items.56,57 Participants were 
asked to indicate their mean intake of each item during the previous year. The 
predefined responses were reported in 12 categories ranging from never to 
more than 8 times/day.  The average daily intakes of foods and nutrients was 
calculated using the FoodCalc program,58 which is based on Danish food 
composition tables. At the study centres the food frequency questionnaires 
were optically scanned and checked for missing values and reading errors 
and uncertainties were checked by technicians with the study participants. 
The food frequency questionnaire was validated against two weeks of 
weighted diet records and correlations between energy adjusted intakes from 
the food-frequency questionnaire and the two-week diet records for PUFA 
were 0.53 for men and 0.28 for women.59 
 
ASSESSMENT OF ADIPOSE TISSUE CONTENT OF FATTY ACIDS 
All participants had an adipose tissue biopsy taken from the subcutaneous fat 
from the buttocks at baseline. A luer lock system (Terumo, Terumo Corp, 
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Tokyo, Japan) was used, which consisted of a needle, a venoject multi-sample 
luer adaptor and an evacuated blood tube according to the method of Beynen 
and Katan.60 All adipose tissue samples were subsequently flushed with 
nitrogen and stored at -150 oC until analysis, where samples were thawed, 
and adipose tissue was removed to a glass and preheated at 50 oC for 10 min. 
Heptane was used to dissolve the fat at 50 oC and fatty acids were 
transesterified by 2 mol/L potassium hydroxide in methanol at 50 oC for 2 min, 
according to IUPAC standard methods for analysis of oils, fats and derivatives. 
Fatty acid composition of adipose tissue was determined by gas 
chromatography on a CP-sil 88 60 m×0.25 mm ID capillary column, consisting 
of a highly substituted, stabilized cyanopropyl stationary phase, using a Varian 
3900 GC with a CP-8400 auto sampler (Varian, Middleburg, The Netherlands) 
equipped with a flame ionization detector. Commercially available standards 
(Nu-check-Prep, Inc., Min, US) were used to identify individual fatty acids and 
helium was used as the carrier gas. The contents of LA, EPA, DPA and DHA 
were given as weight percentage of total fatty acids. The inter-assay 
coefficient of variation for fatty acids in adipose tissue was 1.0% for LA, 6.1% 
for EPA, 4.2% for DPA and 5.2% for DHA. 
 
ASSESSMENT OF COVARIATES 
Participants filled in a lifestyle questionnaire at baseline regarding social 
factors, health status and lifestyle habits during the previous year. Education 
was reported as <7 years, 8 to 10 years, or >10 years. Information on physical 
activity was reported as number of hours per week spent on walking, biking, 
housework, home maintenance, gardening, and sports during summer and 
winter. Smoking habits during the past year were self-reported as frequency 
(never, former, or current), number, and type (cigarettes, cigars, cheroots, and 
tobacco pipes smoked per day). Hypercholesterolemia was also self-reported 
or defined by treatment with lipid-lowering agents. Similarly, data on 
hypertension was self-reported or defined by use of antihypertensive drugs. 
Information on diabetes mellitus was self-reported or defined by use of insulin. 
Information on atrial fibrillation/atrial flutter was found by linkage to the 
National Patient Register using International Classification of Diseases (ICD)-
8 discharge codes 42793 or 42794 or ICD-10 discharge code I489.  
 
Anthropometric measurements (height, weight, and waist circumference) 
were obtained by a technician at baseline. Body mass index (BMI) was 
calculated as weight (kg)/height (m)2. 
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ASSESSMENT OF ISCHEMIC STROKE CASES 
The outcome measure was incident ischemic stroke and ischemic stroke 
subtypes. Potential ischemic stroke cases were obtained by linkage to the 
Danish National Patient Register.61 Participants registered with an ICD-8 
discharge diagnose of 430, 431, 433, 434, 436.01, or 436.90 or an ICD-10 
discharge code of I60, I61, I63, or I64 were considered potential stroke cases. 
The World Health Organization’s definition of stroke as “an acute disturbance 
of focal or global cerebral function with symptoms lasting more than 24 hours 
or leading to death of presumed vascular origin” was used.62 Case records 
were individually reviewed by a physician with neurological experience and 
diagnoses were validated and characterized based on clinical appearance, 
computed tomography, magnetic resonance imaging scan, autopsy records, 
spinal fluid examination, and other relevant information.63 Ischemic stroke 
cases were subtyped according to the TOAST classification and included 
large artery atherosclerosis, cardioembolism, small-vessel occlusion, stroke 
of other etiology, and stroke of undetermined etiology.3 
 
 
STATISTICAL ANALYSES 
All statistical analyses were performed using Stata 14 (StataCorp LP). The 
endpoint in the four studies was total ischemic stroke and ischemic stroke 
subtypes according to the TOAST classification system. Hazard ratios (HR) 
with 95 % confidence intervals (CI) were calculated using sex-stratified Cox 
proportional hazard regression models allowing baseline hazards to differ 
between men and women. Attained age was the underlying time axis and 
observation time for each participant was the period from date of enrollment 
until occurrence of ischemic stroke, death from another cause, emigration, or 
end of follow-up (December 30th, 2009).  
In the substitution analyses, exposures were investigated linearly as 
continuous variables. We included a sum-variable and each component 
separately except for the component to be replaced.64 In the analyses of 
substitution of LA for other macronutrients the sum-variable was made from 
the sum of LA, SFA, MUFA, glycemic carbohydrate and protein in the diet. In 
the analyses of substitution of fish for other food-items the sum-variable was 
made from the sum of intake of fish, red meat and poultry. As the sum-variable 
held the total amount of components constant a higher intake from the 
component that was investigated, implied a concomitant lower intake from the 
component that was not included in the model. Thereby the difference in risk 
of ischemic stroke could be estimated for a 5% higher energy intake of LA and 
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a 5% lower energy intake of either SFA, MUFA or glycemic carbohydrates. 
Also, the risk of ischemic stroke could be estimated with a 150 g/week higher 
intake of fish and a concomitant lower intake of processed or unprocessed red 
meat or poultry. 
Intake of total marine n-3 PUFA, EPA, DPA and DHA was investigated 
according to quartiles using the lowest quartile as the reference. Energy 
contribution from marine n-3 PUFA was too low to be investigated in a 
substitution model. Hence, analyses of dietary intake of total marine n-3 
PUFA, EPA, DPA and DHA exposure were investigated using the residual 
method to energy-adjust these nutrients.65 By using this approach, we were 
able to investigate dietary composition of total marine n-3 PUFA, EPA, DPA 
and DHA in relation to risk of ischemic stroke independent of total energy 
intake. This limits misclassification of intake of nutrients due to differences in 
physical activity, body size and metabolic efficiency.65 
In the adipose tissue analyses exposures were investigated according to 
quartiles using the lowest quartile as the reference. We used a case-cohort 
design, which allowed us to limit costly gas chromatography analyses of 
adipose tissue to all cases and the subcohort. By performing weighted Cox 
regression analyses, HRs could be obtained as if the full cohort had been 
included. Participants were assigned weights, 1 for cases and N/n for 
noncases in the subcohort, where N was the number of noncases in the cohort 
and n was the number of noncases in the subcohort.66 We carried out a Wald 
test for trend across quartiles.  
In the analyses of ischemic stroke subtypes, only participants with a diagnosis 
of the ischemic stroke subtype in question were included as cases. Other 
subtypes of ischemic stroke were censored at the time of diagnosis since their 
risk of another stroke might have been changed.  
Confounders were chosen a priori based on existing literature. We used three 
different models to adjust for potential confounding:  
• Model 1A represented an age -and sex adjusted model. In the 
substitution analyses it also included total energy intake.  
• Model 1B was a socioeconomic and lifestyle adjusted model. In model 
1B, model 1A was further adjusted for: education, waist circumference 
adjusted for BMI, smoking, physical activity, alcohol intake and 
alcohol abstain.  
• In Model 2 we further adjusted for other known risk factors for 
ischemic stroke, which also represented possible intermediate factors 
in the path between the exposures and ischemic stroke and included: 
hypertension, hypercholesterolemia, diabetes mellitus and atrial 
fibrillation/atrial flutter.  
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Restricted cubic splines with three knots were used to adjust for continuous 
variables. We evaluated the proportional hazards assumption in the Cox 
regression analyses by plotting scaled Schoenfeld residuals.  
We used radar charts to investigate possible differences in the underlying 
dietary pattern in relation to intake or adipose tissue content of the 
macronutrient or food in question. Intake of different foods was energy 
adjusted using the residual method. 
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CHAPTER 5. STUDIES 
This thesis is based on four studies conducted within the Diet, Cancer and 
Health cohort (Figure 4). The enrollment process was described in chapter 4. 
 
Figure 4: Flowchart of the study population used in the four studies. 
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Of the 57,053 participants who agreed to participate, we excluded 569 
participants with cancer and 582 participants with a diagnosis of stroke before 
enrollment. The information on covariates was insufficient in 564 participants, 
who were also excluded. Hence the final study population included 55,338 
participants and the subcohort included 3,410 participants.  
Participants were followed for a median of 13.5 years and during that time a 
total of 1879 ischemic strokes occurred. Baseline characteristics of the cohort, 
subcohort and ischemic stroke cases are shown in Table 1. When compared 
to participants in the cohort and in the subcohort, ischemic stroke cases were 
older, and a higher proportion was men. Also, ischemic stroke cases had a 
shorter education and a larger waist circumference, were more likely to be 
smokers, less physically active and had a higher alcohol intake. Furthermore, 
ischemic stroke cases were more likely to have hypercholesterolemia, 
hypertension, diabetes mellitus and atrial fibrillation/atrial flutter when 
compared to the cohort and subcohort.     
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Table 2. Baseline characteristics of the cohort, subcohort and ischemic stroke cases in the Diet, 
Cancer and Health cohort. 
 
 
Cohort Subcohort Ischemic stroke 
cases 
Age 56.1 (50.7-64.2) 56.3 (50.7-64.2) 58.9 (51.0-64.6) 
Sex % (n) 
Male  47.6 (26,351) 54.1 (1,731) 61.9 (1,087) 
Female  52.4 (28,987) 45.9 (1,470) 38.1 (668) 
Education % (n) 
<7 years  32.9 (18,177) 32.9 (1,053) 41.0 (719) 
8-10 years 46.1 (25,515) 45.0 (1,439) 42.6 (747) 
>10 years 21.1 (11,646) 22.2 (709) 16.5 (289) 
BMI (kg/m2) 25.5 (20.5-33.3) 25.8 (20.7-33.4) 26.3 (21.0-34.9) 
Waist circumference (cm) 88.8 (69.0-110.0) 90.0 (69.5-111.0) 93.0 (72.0-116.0) 
Smoking status % (n) 
Non current 64.1 (35,462) 63.9 (2,045) 50.5 (887) 
Current <15 g/d 13.0 (7,214) 13.6 (436) 15.4 (271) 
Current 15 g/d 22.9 (12,662) 22.5 (720) 34.0 (597) 
Physical activity (hours/week) 2.5 (0.0-11.0) 2.5 (0.0-10.5) 2.0 (0.0-11.0) 
Alcohol intake (g/d) 12.9 (0.7-64.6) 13.8 (0.8-65.4) 14.5 (0.5-79.4) 
Alcohol abstain % (n) 
Yes 2.3 (1,271) 2.1 (68) 3.0 (52) 
No 97.7 (54,067) 97.9 (3,135) 97.0 (1,703) 
Hypercholesterolemia % (n) 
Yes 7.4 (4,065) 7.9 (253) 10.8 (190) 
No 50.3 (27,830) 49.3 (1,579) 48.4 (850) 
Unknown 42.4 (23,443) 42.8 (1,369) 40.8 (715) 
Hypertension % (n) 
Yes 16.0 (8,865) 15.7 (502) 28.8 (505) 
No 70.9 (39,226) 71.7 (2,295) 57.7 (1,012) 
Unknown 13.4 (7,147) 12.6 (404) 13.6 (238) 
Diabetes mellitus % (n) 
Yes 2.0 (1,116) 2.0 (65) 4.3 (76) 
No 93.4 (51,660) 92.9 (2,972) 89.6 (1,572) 
Unknown 4.6 (2,562) 5.1 (164) 6.1 (107) 
Atrial fibrillation/atrial flutter % (n) 
Yes 0.8 (54,915) 0.9 (30) 1.4 (24) 
No 99.2 (423) 99.1 (3,171) 98.6 (1,731) 
Values are expressed as medians (5th -95th percentile) and percent (number) for categorical 
variables. BMI indicates body mass index. 
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STUDY I 
Aim 
The aim of the first study was to investigate the association between a higher 
intake of LA and a concomitant lower intake of SFA, MUFA or glycemic 
carbohydrates in relation to ischemic stroke and its subtypes. 
 
Key methods 
Information on diet was assessed from the food frequency questionnaire that 
participants filled in at baseline. Statistical substitution models were used to 
investigate a 5% higher intake of LA and a concomitant lower intake of SFA, 
MUFA or glycemic carbohydrates. We compared participants with identical 
total energy intake and identical intake of macronutrients except for the 
macronutrient to be substituted. We used Cox proportional hazards 
regressions to estimate HRs with 95% CIs for ischemic stroke and its subtypes 
for these substitutions.  
 
Main results 
During follow-up, 1879 ischemic strokes occurred, including 319 cases of 
large artery atherosclerosis, 844 cases of small-vessel occlusion, 102 cases 
of cardioembolism, 98 strokes of other etiology, and 516 strokes of 
undetermined etiology. 
 
A 5% higher intake of LA and a concomitant lower intake of SFA was 
associated with a slightly lower risk of total ischemic stroke and strokes 
caused by large artery atherosclerosis, although not statistically significant. A 
5% higher intake of LA replacing MUFA was associated with a lower risk of 
total ischemic stroke and small-vessel occlusion, although only statistically 
significant for small-vessel occlusions. When a 5% higher intake of LA 
replaced glycemic carbohydrates a statistically non-significant lower risk of 
total ischemic stroke, strokes caused by large artery atherosclerosis and 
small-vessel occlusions were observed.  
 
Main conclusions 
Results from this study suggests that replacing SFA, MUFA or glycemic 
carbohydrate with LA may be associated with a lower risk of ischemic stroke. 
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Table 3. Association between a 5 energy % higher intake of LA and a concomitant lower intake 
of SFA, MUFA or glycemic carbohydrates and risk of ischemic stroke and subtypes 
 LA for SFA LA for MUFA LA for glycemic 
carbohydrates 
 HR (95% CI) HR (95% CI) HR (95% CI) 
Total ischemic stroke 0.98 (0.83–1.16) 0.80 (0.63–1.02) 0.92 (0.78–1.09) 
Large-artery atherosclerosis 0.84 (0.57–1.25) 1.05 (0.58–1.90) 0.96 (0.64–1.44) 
Cardioembolism 1.46 (0.75–2.85) 1.35 (0.51–3.55) 1.55 (0.81–3.00) 
Small-vessel occlusion 0.96 (0.75–1.23) 0.67 (0.46–0.96) 0.82 (0.64–1.05) 
Stroke of other etiology 0.93 (0.45–1.91) 0.85 (0.29–2.45) 0.98 (0.47–2.05) 
Adjusted for baseline age, sex, education, energy intake, waist circumference adjusted for BMI, smoking, 
physical activity, alcohol intake and alcohol abstain (Model 1B). LA indicates linoleic acid; SFA, saturated 
fatty acids; MUFA, monounsaturated fatty acids; HR, hazard ratio and CI, confidence interval. 
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STUDY II 
Aim 
The aim of this study was to investigate the association between adipose 
tissue content of LA (an objective marker of intake and metabolism) and the 
risk of ischemic stroke and its subtypes.  
 
Key methods 
We conducted a case-cohort study nested within the Diet, Cancer and Health 
cohort. Ischemic stroke cases and a randomly drawn subcohort (n = 3500) 
had their adipose tissue biopsies analyzed by gas chromatography. Data were 
analyzed using weighted Cox proportional hazard regression.   
 
Main results 
Adipose tissue biopsies were available for 3203 participants in the subcohort 
and for 1755 ischemic stroke cases including 300 strokes caused by large 
artery atherosclerosis, 781 strokes caused by small-vessel occlusion, 99 
strokes caused by cardioembolism, 91 strokes of other etiology, and 484 
strokes of undetermined etiology. 
 
Comparing the highest and the lowest quartiles of adipose tissue content of 
LA, we found a statistically significant inverse association with the rate of total 
ischemic stroke and large artery atherosclerosis. For small-vessel occlusion 
an inverse association with adipose tissue content of LA was found, although 
not statistically significant. There was no clear association between adipose 
tissue content of LA and the rate of cardioembolism.  
 
Main conclusions 
The content of LA in adipose tissue was statistically significantly inversely 
associated with the risk of total ischemic stroke and stroke caused by large 
artery atherosclerosis and statistically non-significantly inversely associated 
with small-vessel occlusion.  
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Table 4. Adipose tissue content of LA in quartiles and association with ischemic stroke and 
ischemic stroke subtypes. 
 LA 
 HR (95% CI) 
Total ischemic stroke 
Q1 1 
Q2 0.92 (0.77–1.09) 
Q3 0.85 (0.71–1.02) 
Q4 0.78 (0.65–0.93) 
Ptrend P=0.004 
Large artery atherosclerosis 
Q1 1 
Q2 0.72 (0.51–1.01) 
Q3 0.84 (0.61–1.17) 
Q4 0.61 (0.43–0.88) 
Ptrend P=0.021 
Cardioembolism 
Q1 1 
Q2 1.28 (0.75–2.19) 
Q3 0.71 (0.37–1.37) 
Q4 0.86 (0.46–1.59) 
Ptrend P=0.311 
Small-vessel occlusion 
Q1 1 
Q2 0.90 (0.72–1.13) 
Q3 0.87 (0.69–1.03) 
Q4 0.87 (0.69–1.11) 
Ptrend P=0.236 
Adjusted for baseline age, sex, education, waist 
circumference adjusted for body mass index, smoking, 
physical activity, alcohol intake and alcohol abstain (Model 
1B). LA indicates linoleic acid; Q, quartile; HR, hazard ratio 
and CI, confidence interval. 
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STUDY III 
Aim 
The aim of this study was to investigate the association between total marine 
n-3 PUFA, EPA and DHA from dietary intake and adipose tissue content in 
relation to ischemic stroke and its subtypes. 
 
Key methods 
Dietary intake of total marine n-3 PUFA, EPA and DHA was expressed as 
energy-adjusted intake in g/d. We used Cox proportional hazard regressions 
to analyze data of dietary intake. For the analyses of adipose tissue content 
of total marine n-3 PUFA, EPA and DHA we used a case-cohort design. 
Adipose tissue biopsies were analyzed using gas chromatography and a 
weighted Cox proportional hazard regression was used to analyze data.  
 
Main results 
The cohort included 55,338 participants for the analyses of dietary intake. 
During follow-up, 1879 participants developed ischemic stroke for whom 1755 
adipose biopsies were available while 3201 participants had an adipose 
biopsy available within the subcohort. Ischemic stroke cases were distributed 
as given below with available adipose tissue biopsies in parentheses: 319 
strokes due to large artery atherosclerosis (300), 102 strokes due to 
cardioembolism (99), 844 small-vessel occlusion strokes (781), 98 strokes of 
other etiology (91), and 516 strokes of undetermined etiology (484).  
 
There was no association between intake or adipose tissue content of total 
marine n-3 PUFA and total ischemic stroke. However, adipose tissue content 
of EPA showed an inverse association with total ischemic stroke. Also, lower 
rates of large artery atherosclerosis were seen with higher intakes of total 
marine n-3 PUFA, EPA and DHA and higher adipose tissue content of EPA. 
Higher rates of cardioembolism were seen with higher intakes of total marine 
n-3 PUFA and DHA as well as with higher adipose tissue content of total 
marine n-3 PUFA and DHA. The EPA content in adipose tissue was inversely 
associated with small-vessel occlusion. 
 
Main conclusions 
Dietary intake and adipose tissue content of EPA was associated with a lower 
risk of most types of ischemic stroke, while total n-3 PUFA and DHA showed 
inconsistent results.  
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Table 5. Dietary intake of total marine n-3 PUFA, EPA and DHA in quartiles and association 
with ischemic stroke and ischemic stroke subtypes. 
  
 Total marine 
n-3 PUFA 
EPA DHA 
 HR (95% CI) HR (95% CI) HR (95% CI) 
Total ischemic stroke 
Q1 1 1 1 
Q2 1.06 (0.93-1.21) 1.05 (0.92-1.20) 1.08 (0.95-1.23) 
Q3 1.06 (0.93-1.21) 1.09 (0.96-1.24) 1.02 (0.90-1.67) 
Q4 1.06 (0.93-1.20) 1.01 (0.89-1.15) 1.06 (0.94-1.21) 
Ptrend P = 0.458 P = 0.732 P = 0.513 
Large artery atherosclerosis  
Q1 1 1 1 
Q2 0.97 (0.72-1.30) 0.86 (0.64-1.16) 0.90 (0.67-1.22) 
Q3 0.88 (0.65-1.19) 0.82 (0.60-1.11) 0.86 (0.63-1.16) 
Q4 0.69 (0.50-0.95) 0.66 (0.48-0.91) 0.72 (0.53-0.99) 
Ptrend P = 0.020 P = 0.012 P = 0.043 
Cardioembolism 
Q1 1 1 1 
Q2 1.36 (0.69-2.66) 1.17 (0.58-2.35) 0.97 (0.50-1.89) 
Q3 1.49 (0.78-2.88) 2.34 (1.27-4.30) 1.27 (0.68-2.36) 
Q4 2.50 (1.38-4.53) 2.02 (1.09-3.73) 2.12 (1.21-3.69) 
Ptrend P = 0.001 P = 0.005 P = 0.002 
Small-vessel occlusion 
Q1 1 1 1 
Q2 1.15 (0.94-1.40) 1.14 (0.94-1.38) 1.26 (1.04-1.54) 
Q3 1.20 (0.98-1.45) 1.16 (0.96-1.41) 1.17 (0.96-1.43) 
Q4 1.06 (0.87-1.30) 1.05 (0.86-1.28) 1.13 (0.93-1.38) 
Ptrend P = 0.518 P = 0.647 P = 0.411 
Adjusted for baseline age, sex, education, waist circumference adjusted 
for body mass index, smoking, physical activity, alcohol intake and 
alcohol abstain (Model 1B).  PUFA indicates polyunsaturated fatty acids; 
EPA, eicosapentaenoic acid; DHA, docosapentaenoic acid; Q, quintile; 
HR, hazard ratio and CI, confidence interval. 
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Table 6. Adipose tissue content of total marine n-3 PUFA, EPA and DHA in quartiles and 
association with ischemic stroke and ischemic stroke subtypes. 
 
 
 
  
 Total marine 
n-3 PUFA 
EPA DHA 
 HR (95% CI) HR (95% CI) HR (95% CI) 
Total ischemic stroke 
Q1 1 1 1 
Q2 0.98 (0.82-1.17) 0.91 (0.77-1.07) 0.92 (0.77-1.10) 
Q3 1.12 (0.94-1.33) 0.66 (0.55-0.81) 1.09 (0.91-1.30) 
Q4 1.08 (0.90-1.30) 0.74 (0.62-0.88) 1.00 (0.83-1.20) 
Ptrend P = 0.213 P < 0.001 P = 0.580 
Large artery atherosclerosis  
Q1 1 1 1 
Q2 0.86 (0.61-1.22) 0.96 (0.70-1.32) 0.94 (0.67-1.32) 
Q3 1.09 (0.78-1.52) 0.64 (0.43-0.94) 1.08 (0.77-1.52) 
Q4 0.78 (0.53-1.13) 0.52 (0.36-0.76) 0.79 (0.54-1.16) 
Ptrend P = 0.404 P < 0.001 P = 0.386 
Cardioembolism 
Q1 1 1 1 
Q2 2.08 (1.04-4.15) 1.13 (0.61-2.11) 1.37 (0.71-2.64) 
Q3 2.04 (1.03-4.04) 1.06 (0.52-2.14) 1.64 (0.87-3.10) 
Q4 2.63 (1.33-5.19) 1.52 (0.82-2.81) 2.00 (1.04-3.84) 
Ptrend P = 0.007 P = 0.183 P = 0.030 
Small-vessel occlusion 
Q1 1 1 1 
Q2 0.91 (0.72-1.15) 0.84 (0.68-1.04) 0.86 (0.68-1.09) 
Q3 1.05 (0.83-1.32) 0.61 (0.47-0.79) 1.07 (0.85-1.34) 
Q4 0.99 (0.79-1.26) 0.69 (0.55-0.88) 0.92 (0.72-1.17) 
Ptrend P = 0.768 P < 0.001 P = 0.916 
Adjusted for baseline age, sex, education, waist circumference adjusted 
for body mass index, smoking, physical activity, alcohol intake and 
alcohol abstain (Model 1B).   PUFA indicates polyunsaturated fatty acids; 
EPA, eicosapentaenoic acid; DHA, docosapentaenoic acid; Q, quintile; 
HR, hazard ratio and CI, confidence interval. 
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STUDY IV 
Aim 
The aim of this study was to investigate substitutions of one serving of fish per 
week for one serving of red meat or poultry in relation to ischemic stroke and 
its subtypes.   
 
Key methods 
Information on food-items was obtained from the food-frequency 
questionnaire. We used statistical food substitution models to investigate the 
rate of ischemic stroke and its subtypes when intake of 150 g/week of total, 
lean or fatty fish replaced processed or unprocessed red meat or poultry. Cox 
proportional hazard regression analyses were used to estimate associations 
between food substitutions and ischemic stroke risk.  
 
Main results 
 
A total of 1879 participants developed ischemic stroke, including 319 cases 
caused by large artery atherosclerosis, 844 small-vessel occlusions, 102 
cases caused by cardioembolisms, 98 strokes of other etiology, and 516 
strokes of undetermined etiology. 
 
Total, lean or fatty fish replacing red meat or poultry was not associated with 
the rate of total ischemic stroke. However, a statistically significant lower rate 
of large artery atherosclerosis was found, when fish replaced processed and 
unprocessed red meat. When total fish replaced poultry a statistically 
significant higher rate of cardioembolism was found. A statistically significant 
lower rate of small-vessel occlusion was found when unprocessed red meat 
was replaced by fatty fish.  
 
Main conclusions 
In conclusion, replacement of red meat with fish was not associated with the 
risk of total ischemic stroke but was associated with a lower risk of large artery 
atherosclerosis.  
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Table 7. Substitution of total fish for processed red meat, unprocessed red meat or poultry and 
total ischemic stroke and ischemic stroke subtypes. 
 Total fish 
 Processed red 
meat 
Unprocessed 
red meat 
Poultry 
 HR (95% CI) HR (95% CI) HR (95% CI) 
Total ischemic stroke 0.97 (0.91-1.02)  
 
0.97 (0.93-1.02)  
 
1.00 (0.93-1.07)  
 Large artery atherosclerosis 0.78 (0.67-0.90)  
 
0.87 (0.75-0.99)  
 
0.83 (0.69-1.01)  
 Cardioembolism 1.26 (0.99-1.59)  
 
1.14 (0.96-1.35)  
 
1.42 (1.04-1.93)  
 Small-vessel occlusion 1.00 (0.92-1.10)  
 
0.95 (0.88-1.02)  
 
0.94 (0.85-1.04)  
 Adjusted for baseline age, sex, energy intake, education, waist circumference adjusted for 
body mass index, smoking, physical activity, alcohol intake and alcohol abstain (Model 
1B). HR indicates hazard ratio and CI, confidence interval. 
 
Table 8. Substitution of lean fish for processed red meat, unprocessed red meat or poultry and 
total ischemic stroke and ischemic stroke subtypes. 
 Lean fish 
 Processed red 
meat 
Unprocessed 
red meat 
Poultry 
 HR (95% CI) HR (95% CI) HR (95% CI) 
Total ischemic stroke 0.98 (0.91-1.06)  
 
 
0.99 (0.92-1.06)  
 
1.01 (0.93-1.11)  
 Large artery atherosclerosis 0.77 (0.63-0.95)  
 
0.86 (0.70-1.06)  
 
0.83 (0.65-1.05)  
 Cardioembolism 1.28 (0.97-1.71)  
 
1.16 (0.92-1.47)  
 
1.45 (1.02-2.06)  
 Small-vessel occlusion 1.06 (0.95-1.19)  
 
1.00 (0.91-1.11)  
 
1.00 (0.88-1.13)  
 Adjusted for baseline age, sex, energy intake, education, waist circumference adjusted for 
body mass index, smoking, physical activity, alcohol intake and alcohol abstain (Model 
1B). HR indicates hazard ratio and CI, confidence interval. 
 
Table 9. Substitution of fatty fish for processed red meat, unprocessed red meat or poultry and 
total ischemic stroke and ischemic stroke subtypes. 
 Fatty fish 
 Processed red 
meat 
Unprocessed 
red meat 
Poultry 
 HR (95% CI) HR (95% CI) HR (95% CI) 
Total ischemic stroke 0.95 (0.87-1.03)  
 
0.95 (0.88-1.04)  
 
0.98 (0.89-1.08)  
 Large artery atherosclerosis 0.78 (0.61-0.98)  
 
0.87 (0.69-1.09)  
 
0.84 (0.65-1.09)  
 Cardioembolism 1.22 (0.87-1.70)  
 
1.10 (0.82-1.48)  
 
1.37 (0.93-2.02)  
 Small-vessel occlusion 0.93 (0.81-1.07)  
 
0.88 (0.77-0.99)  
 
0.87 (0.75-1.01)  
 Adjusted for baseline age, sex, energy intake, education, waist circumference adjusted for 
body mass index, smoking, physical activity, alcohol intake and alcohol abstain (Model 
1B). HR indicates hazard ratio and CI, confidence interval. 
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CHAPTER 6. METHODOLOGICAL 
CONSIDERATIONS 
In observational cohort studies, bias can occur due to problems with selection, 
information or confounding. Potential biases in the four studies in this thesis 
are discussed below.  
 
SELECTION PROBLEMS 
Selection bias may arise from systematic errors in procedures used to recruit 
participants into the study. Such errors may occur if the association between 
exposure and disease is different for participants and non-participants.  An 
advantage of a prospective cohort study design is that the information on 
exposures is assessed at inclusion when participants are free from the 
disease of interest.  
Selection bias can also be introduced if the investigated exposure gives rise 
to different completeness of follow-up. Ischemic stroke cases within the Diet, 
Cancer and Health cohort were identified through linkage to The Danish 
Patient Register, independently of the exposure in question. This made the 
follow-up almost complete, limiting the risk of selection bias.  
In the Diet, Cancer and Health cohort, only 35% of those invited, agreed to 
participate and participants of a higher socioeconomic status were slightly 
overrepresented56 but the investigated associations are believed not to differ 
across socio-economic groups. However, this is not selection bias but a 
problem with generalizability. Another generalizability issue is that participants 
in the Diet, Cancer and Health cohort were at recruitment living in and around 
Copenhagen and Aarhus in Denmark. Because participants were at least 50 
years at inclusion, our results may only be applicable for people this age. 
Moreover, the study population was nearly exclusively Caucasians and 
findings may therefore not apply to other ethnic groups.  
 
INFORMATION PROBLEMS 
Information problems occur when measurements of exposure or outcome are 
not valid. Information problems may be introduced by the observer, by the 
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participants in the study or by the measurement instruments. For categorical 
variables, information problems are often referred to as misclassification.  
Misclassification of exposure  
Information on dietary intake in Study I, III and IV was assessed from self-
reported food frequency questionnaires at baseline. Dietary food frequency 
questionnaires are known to be prone to measurement errors. However, the 
food frequency questionnaire used in this study, has been carefully developed 
and validated against two times seven days of weighted dietary records.57,59 
The food frequency questionnaires were designed to assess usual frequency 
of consumption during the last 12 months and therefore reflecting a relative 
long-term dietary intake. However, multiple measurements during follow-up of 
dietary intake would have captured potential dietary changes and would have 
been preferable to a single baseline measurement. Intake of fatty acids is 
generally problematic to assess through food frequency questionnaires due to 
difficulty in quantifying fat used in food preparation. Intake of LA is particularly 
difficult to assess because it is consumed from many different sources and 
can be hard to distinguish from other PUFA such as ALA.42 
In Study II and III the exposure investigated was adipose tissue content of 
different PUFA. Adipose tissue provides an objective measure of fatty acid 
composition reflecting the endogenous exposure of individual fatty acids of 
the body.67 Content of fatty acids in adipose tissue is influenced by 
consumption, uptake, synthesis, metabolism and release. LA cannot be 
synthetized in the body, while EPA and DHA can be synthetized from ALA, 
although to a limited extent. Therefore, adipose tissue content is a good 
biomarker of LA, EPA and DHA intake. Because of a slow turnover time, 
adipose tissue has been proposed to reflect dietary intake of these fatty acids 
during the previous 1-3 years.67 However, adipose tissue biopsies were only 
obtained at baseline and potential changes in fatty acids in adipose tissue 
during follow-up were not assessed. Also, fatty acids in adipose tissue are 
measured as percentage of total fatty acids, and therefore influenced by the 
amount of other fatty acids. Food-frequency questionnaires and adipose 
tissue biopsies each have their advantages and disadvantages when used to 
examine long-term intake of LA, EPA and DHA. However, as complementary 
information they are useful tools.68 
Misclassification of outcomes 
The outcome in the four studies was ischemic stroke and its subtypes. 
Information on ischemic stroke cases was obtained by linkage with the Danish 
National Patient Register independently of the exposure in question. Thus, 
information bias is of no concern. Moreover, all cases of stroke were 
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individually validated.63 Ischemic stroke cases were subtyped according to the 
TOAST classification system but a subset of 30 % with incomplete evaluations 
or two or more potential causes identified were categorized as stroke of 
undetermined etiology. Therefore, many ischemic stroke cases could not be 
classified into the three major etiological subtypes of strokes.  
 
CONFOUNDING 
A confounder is a factor that biases the association aimed to be studied, 
unless it is controlled for. It is associated with the exposure and independently 
affect the risk of the outcome. However, if a factor is an intermediate step in 
the causal pathway between the exposures of interest and the disease in 
question, it is not a confounder but a part of the effect being studied.69,70 
Confounding is an important threat to the internal validity of observational 
studies. In studies of diet and diseases a confounder may introduce a false 
association between diet and disease. Importantly, participants who eat 
healthy are more likely to follow a healthy lifestyle e.g. by drinking less alcohol, 
not smoke and being physically active and if those variables are not controlled 
for it may distort the true relationship between the exposure being examined 
and the disease of interest. In the Diet, Cancer and Health cohort detailed 
information on social factors and lifestyle habits were collected at baseline 
from a self-reported lifestyle questionnaire. Also, anthropometric 
measurements were obtained at baseline. Thereby the participants provided 
information on potential confounders that we adjusted for, which limits but 
does not eliminate residual confounding.  
Adjustment for potential confounders was applied in steps in different models. 
The first model represented an age and sex adjusted model (Model 1A). In 
the second model education and lifestyle factors were added to Model 1A and 
named Model 1B. For all analyses, when adding these covariates, the patterns 
of associations remained the same, although associations were weakened, 
indicating confounding. In Model 2 we added other known risk factors, 
hypercholesterolemia, hypertension, diabetes mellitus and atrial 
fibrillation/atrial flutter which may also be considered intermediate factors 
between the exposures and ischemic stroke. However, adjustment may 
introduce collider stratification bias and induce associations between factors 
affecting these variables. Thus, we considered Model 1B our main analyses 
with the most straightforward interpretation.  
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When ischemic strokes were subtyped according to the TOAST-classification 
system, the number of cases with cardioembolism and stroke of other etiology 
was low. This limited adjustment for potential confounders and risk factors.  
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CHAPTER 7. DISCUSSION 
The aim of this thesis was to describe the association between n-6 and marine 
n-3 PUFA from dietary intake and content in adipose tissue and the risk of 
ischemic stroke and its subtypes. Dietary intake of LA replacing SFA, MUFA 
or glycemic carbohydrates was investigated in relation to ischemic stroke and 
its subtypes (Study I). Results indicated a lower risk of ischemic stroke and its 
subtypes with these substitutions. Also, adipose tissue content of LA was 
inversely related to ischemic stroke and its subtypes (Study II). We 
investigated both dietary intake and adipose tissue content of total marine n-
3 PUFA, EPA and DHA in relation to ischemic stroke (Study III). The adipose 
tissue content of EPA was associated with a lower risk of most types of 
ischemic stroke while intake of total marine n-3 PUFA, EPA and DHA was 
associated with a lower risk of large artery atherosclerosis. Furthermore, 
consumption of fish replacing red meat or poultry was investigated in relation 
to ischemic stroke and its subtypes (Study IV). We found no association with 
total ischemic stroke with these substitutions but a lower risk of stroke due to 
large artery atherosclerosis was found when fish replaced red meat.  
 
LINOLEIC ACID AND THE RISK OF ISCHEMIC STROKE 
In Study I, a higher intake of LA and a concomitant lower intake of SFA, MUFA 
or glycemic carbohydrates was associated with a lower risk of ischemic stroke 
and its subtypes. These results were in agreement with our hypothesis. To 
date, this is to our knowledge the first study to investigate associations 
between substitution of LA for other macronutrients and ischemic stroke and 
its subtypes.  
The association between dietary intake of n-6 PUFA (LA + AA) and ischemic 
stroke was investigated in The Swedish Mammography Cohort.71 During 10.4 
years of follow-up, 1310 participants developed ischemic stroke. No 
association was found between intake of n-6 PUFA and risk of ischemic stroke 
(HR: 0.96, 95% CI: 0.80-1.15, when comparing the highest and the lowest 
quintile). However, in this study substitutions were not specified.  
While no other study has seemingly investigated substitution of LA for other 
macronutrients in relation to risk of ischemic stroke, the substitution aspect 
has been investigated in relation to another atherosclerotic disease, CHD. 
Hence, in a meta-analysis of 13 prospective cohort studies and a total of 
310,602 participants Farvid et al.72 found a lower risk of CHD when a 5% 
energy intake of LA replaced carbohydrates (HR: 0.90 95% CI, 0.85–0.94) or 
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SFA (HR: 0.91; 95% CI: 0.87–0.96). Similarly, another meta-analysis by 
Jakobsen et al.73 of 11 prospective cohort studies and a total of 344,696 
participants reported that a 5% higher intake of PUFA and a concomitant lower 
intake of SFA was associated with a lower risk of CHD (HR: 0.87; 95% CI: 
0.77, 0.97).  
Study II supports our a priori hypothesis that adipose tissue content of LA was 
inversely associated with risk of ischemic stroke and its subtypes. To our 
knowledge the association between adipose tissue content of LA has not been 
investigated previously, however, studies using serum content as a biomarker 
of LA has been investigated in relation to total ischemic stroke. Thus, in the 
Cardiovascular Health Study74 the content of LA in plasma phospholipids was 
investigated in relation to ischemic stroke. In this prospective cohort study, 
362 ischemic strokes occurred during 12.3 years of follow-up. Participants in 
the highest quintile of plasma phospholipid LA had a lower risk of ischemic 
stroke compared to participants in the lowest quintile, although not statistically 
significant (HR: 0.88; 95% CI: 0.61; 1.27). The association between plasma 
phospholipid LA was also investigated in the Kuopio Ischemic Heart Disease 
Risk Factor Study75 and in this prospective cohort study, with a follow-up time 
of 21.2 years and 153 cases of ischemic stroke, no association between 
serum LA and ischemic stroke was found (HR: 1.07; 95% CI: 0.68-1.67, when 
comparing the highest and the lowest quartile of LA). Three nested case-
control studies have investigated serum LA in relation to ischemic stroke. 
Yaemsiri et al.76 included 964 ischemic stroke cases and found that serum LA 
was inversely associated with ischemic stroke, although not statistically 
significant. Iso et al.77 included 122 ischemic stroke cases and found an 
inverse association between serum LA and ischemic stroke, which was 
statistically significant. However, DeGoede at al.78 included 95 ischemic stroke 
cases and found no association between serum LA and risk of ischemic 
stroke. A possible mechanism for LA to reduce ischemic stroke risk is through 
beneficial effects on blood lipids. Thus, a meta-analysis of 60 trials showed 
that replacing carbohydrates with polyunsaturated fat (mainly LA) was 
associated with a lower plasma LDL cholesterol.52 Other possible biologic 
mechanisms by LA could be a lowering of blood pressure79 or an improvement 
of insulin sensitivity.80  
Evidence from the radar chart in or Study II, implied that a high adipose tissue 
content of LA was associated with overall healthier eating habits and results 
can therefore not be directly interpreted as associations for LA independently 
of eating patterns associated with LA intake. Combing evidence from our 
study with other published results, however, suggests a beneficial association 
of LA consumption, or a healthy diet including LA, on risk of ischemic stroke.  
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TOTAL MARINE N-3 PUFA, EPA AND DHA AND THE RISK OF 
ISCHEMIC STROKE 
In Study III, we investigated the association of dietary intake of total marine n-
3 PUFA, EPA and DHA in relation to ischemic stroke. Neither intake of total 
marine n-3 PUFA, EPA nor DHA was associated with the risk of ischemic 
stroke. However, intake of total marine n-3 PUFA, EPA and DHA was 
inversely associated with the risk of stroke due to large artery atherosclerosis. 
To our knowledge, no other studies have evaluated intake of total marine n-3 
PUFA, EPA and DHA in relation to ischemic stroke subtypes. However, six 
other prospective cohort studies have investigated the association between 
intake of EPA + DHA and total ischemic stroke.  
In the Cohort of Swedish Men,81 intake of EPA + DHA was investigated in 
relation to ischemic stroke. In this prospective cohort study, including 2286 
ischemic stroke cases, no association was found between intake of EPA + 
DHA and risk of ischemic stroke (HR: 1.09; 95% CI: 0.94–1.26, when 
comparing the highest and the lowest quartile) after 12 years of follow-up. The 
association between intake of EPA + DHA and ischemic stroke was also 
investigated in the Swedish Mammography Cohort.71 In this prospective 
cohort study, women were followed for a mean of 10.4 years and 1,310 
developed ischemic stroke. Intake of EPA + DHA was inversely associated 
with ischemic stroke risk, and when comparing the highest with the lowest 
quintile a HR of 0.83 (95% CI: 0.69–0.99) was found. The Health Professional 
Follow-up Study82  followed men for 12 years and 377 developed an ischemic 
stroke. There was no dose-response association between intake of EPA + 
DHA and ischemic stroke. However, lower risks of ischemic stroke were found 
in each quintile except for the highest quintile compared to the lowest one 
(HR: 0.73; 95% CI: 0.43-1.25). In the Finnish Mobile Clinic Health Examination 
Survey,83 with 28 years of follow-up and 364 ischemic stroke cases no 
association was found between intake of EPA + DHA and ischemic stroke 
(HR: 0.91; 95% CI: 0.66-1.26 when comparing the highest with the lowest 
quartile of intake). In contrast, a lower risk of ischemic stroke was found 
among women in the highest quintile compared to the lowest quintile of EPA 
+ DHA intake (RR: 0.73; 95% CI: 0.43-1.25), although not statistically 
significant in the Nurses’ Health Study.77 Finally, in the Monitoring Project on 
Risk Factors for Chronic Diseases (Morgen) study,84  inverse but not 
statistically significant associations were found between intake of EPA + DHA 
and risk of ischemic stroke for men (HR: 0.62; 95% CI: 0.29–1.35, comparing 
the highest with the lowest quartile of intake) and women (HR: 0.85; 95% CI: 
0.45–1.60, comparing the highest with the lowest quartile of intake).  
None of the studies mentioned above studied EPA and DHA separately in 
relation to ischemic stroke. However, EPA and DHA are consumed from the 
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same dietary sources and supposed to be highly correlated. In contrast, 
adipose tissue content of EPA and DHA offers an objective marker of 
individual fatty acids and is considered the gold standard according to a slow 
turnover time and therefore a good measure of long-time body availability of 
marine n-3 PUFA.67  
In Study III, we also investigated adipose tissue content of total marine n-3 
PUFA, EPA and DHA in relation to risk of ischemic stroke. Total marine n-3 
PUFA and DHA showed no consistent association with ischemic stroke or its 
subtypes, but adipose tissue content of EPA was inversely associated with 
total ischemic stroke, stroke due to large artery atherosclerosis and small-
vessel occlusions. To our knowledge, this is the only study reported to 
investigate adipose tissue content of total marine n-3 PUFA, EPA and DHA in 
relation to risk of ischemic stroke and its subtypes. However, short-term 
biomarkers of EPA, DPA and DHA have been investigated in relation to 
ischemic stroke and its subtypes in three other studies. Thus, a recent 
prospective study85 investigated the content of EPA and DHA in plasma 
phospholipid in relation to ischemic stroke using pooled data from 3 cohorts: 
Cardiovascular Health Study, Nurses’ Health Study and Health Professional 
Follow-Up Study, with a total of 953 ischemic stroke cases identified. When 
comparing the highest with the lowest quartile of DHA it was associated with 
a lower risk of total ischemic stroke and atherothrombotic stroke (large artery 
atherosclerosis + small-vessel occlusion) while there was no association 
between EPA and total ischemic stroke or atherothrombotic stroke. These 
findings opposed our findings of inverse associations between EPA, but not 
DHA, and ischemic stroke and its subtypes. Moreover, in a nested case-
control study including 964 ischemic stroke cases, Yaemsiri et al.76 found that 
serum DHA but not EPA was inversely associated with risk of total ischemic 
stroke and ischemic stroke subtypes. Finally, in another nested case-control 
study including 144 ischemic stroke cases, Iso et al.86 reported no association 
between serum levels of total marine n-3 PUFA, EPA or DHA and the risk of 
ischemic stroke or its subtypes.   
Three other studies have investigated biomarkers of marine n-3 PUFA in 
relation to total ischemic stroke risk. In The Cardiovascular Health Study87 
which is a prospective cohort study of 319 ischemic stroke cases, no 
association was found between plasma phospholipid EPA (HR: 1.09; 95% CI: 
0.76–1.57) and risk of ischemic stroke. However, when comparing the highest 
and the lowest quartile of plasma phospholipid lower risks of ischemic stroke 
were found for DHA (HR: 0.74; 95% CI: 0.50–1.10) and total marine n-3 PUFA 
(HR: 0.63; 95% CI: 0.43–0.94). In the Kuopio Ischemic Heart Disease Risk 
Factor Study, which included 153 ischemic stroke cases, no association was 
found between serum EPA (HR: 1.27; 95% CI: 0.80-2.00), DHA (HR: 1.01; 
95% CI: 0.70-1.69) or total marine n-3 PUFA (HR: 0.98; 95% CI: 0.64-1.51) 
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and ischemic stroke risk, when comparing the highest and the lowest quartile. 
Finally, in a case-control study nested in the prospective MORGAN study 93 
ischemic stroke cases were identified with no association was found between 
the sum of EPA and DHA from plasma cholesteryl esters and ischemic stroke 
risk.  
The mechanisms by which marine n-3 PUFA may reduce the risk of ischemic 
stroke include beneficial effects on blood pressure, plasma triglycerides, and 
platelet aggregability and inflammation.38 In general, other studies have 
reported an association between biomarkers of DHA but not EPA on ischemic 
stroke risk. In contrast, in our study, adipose tissue content of EPA, but not 
DHA, was inversely associated with total ischemic stroke, large artery 
atherosclerosis and small-vessel occlusion, suggesting a protective effect of 
EPA against atherosclerotic disorders. Two randomized, placebo-controlled 
trials have investigated supplementation with highly purified EPA. In a sub-
study of the Japan Eicosapentaenoic acid Lipid Intervention Study (Jelis),88 
supplementation with  1.8 g of purified EPA in hypercholesterolemic subjects 
a lower risk of cerebral thrombosis was found in a secondary prevention 
subgroup, although not statistically significant (HR: 0.72; 95% CI 0.50–1.00). 
Recently, the Reduce-it trial89 investigated the effect of a supplement with 4 g 
of EPA in 8179 patients with established cardiovascular disease or risk factors 
and found a lower risk of fatal and nonfatal stroke among participants 
receiving EPA compared to placebo (HR: 0.72; 95% CI: 0.55-0.93). However, 
the study reported results only on total stroke without separating ischemic and 
hemorrhagic events.  
Both EPA and DHA have been shown to lower serum triglyceride levels, 
however DHA has also been found in some studies to raise plasma LDL 
cholesterol levels.89–92 LDL cholesterol is a key component of atherosclerosis, 
thus our different results of ischemic stroke subtypes seen among adipose 
tissue content of EPA and DHA might be related to effects on plasma LDL 
cholesterol levels.  
In Study IV, dietary intake of fish replacing red meat or poultry was 
investigated in relation to risk of ischemic stroke and its subtypes. One portion 
of fish per week (corresponding to 150 g) replaced a portion of red meat or 
poultry. We found no association with total ischemic stroke with these 
substitutions but a lower risk of stroke due to large artery atherosclerosis when 
fish replaced red meat. Also, when unprocessed red meat and poultry was 
replaced by fatty fish lower risks of small-vessel occlusions were seen.  
Several studies have evaluated intake of fish in relation to risk of ischemic 
stroke and some but not all found an inverse association.93–95 However, most 
studies have adjusted for total energy intake in the analyses and when total 
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energy intake is included in the analyses an isoenergetic substitution model is 
created and a higher intake of the investigated food or macronutrient implies 
a lower intake of all other foods. Hence a substitution model is created, 
although rarely specified and the replacement food should be defined in the 
models. In the Nurses’ Health Study, which is a prospective cohort study 
substitution of one serving a day of fish for red meat or poultry was also 
investigated.96 A total of 4,030 strokes were identified and lower risks of 
strokes were found when fish replaced red meat (RR: 0.83; 95% CI: 0.70-
1.00) and when poultry replaced fish (RR: 0.89; 95% CI: 0.68-1.16). However, 
substitutions of food groups were only investigated in relation to total stroke 
hence results are not directly comparable to our results.  
In conclusion, combining our results with results from other studies may imply 
a beneficial effect of fish and marine n-3 PUFA intake on ischemic stroke risk, 
in particular strokes caused by large artery atherosclerosis although the 
associations between EPA and DHA and risk of ischemic stroke has differed 
between studies. Furthermore, results from our study suggest that the content 
of EPA in adipose tissue is inversely associated with ischemic stroke and its 
subtypes.  
Ischemic stroke is a heterogenous disorder with mixed etiology and we 
hypothesized that associations of n-6 and marine n-3 PUFA may differ among 
subtypes of ischemic stroke. The TOAST classification system3 offers a 
method for subtyping ischemic stroke according to etiology. Adipose tissue LA 
and EPA were inversely associated with strokes due to large artery 
atherosclerosis. Lower risks of large artery atherosclerosis were also seen 
with high intakes of total and individual marine n-3 PUFA as well as when SFA 
was replaced with LA and when red meat or poultry was replaced with fish.  
Strokes due to small-vessel occlusion was the largest subgroup of ischemic 
stroke comprising more than 800 cases. Adipose tissue content of EPA was 
inversely associated with small-vessel occlusion. Also, when LA replaced 
MUFA or glycemic carbohydrates and when fatty fish replaced unprocessed 
red meat or poultry a lower risk of small-vessel occlusion was found. The 
biological mechanisms between PUFA and small-vessel occlusion are not 
entirely clear. Though there is an atherosclerotic component in the 
development small-vessel occlusion, one of the most important risk factors is 
hypertension. It is therefore of potential significance that intake of fish and 
marine n-3 PUFA are known to slightly lower blood pressure.97 
We found no association between neither dietary substitution nor adipose 
tissue content of LA and strokes due to cardioembolism in Study I and II. 
However, a statistically significant higher risk of cardioembolism was found 
with a high intake and high adipose tissue content of marine n-3 PUFA in 
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Study III. Also, results from Study IV indicated higher risks of cardioembolism, 
when fish replaced red meat or poultry. The reason for this higher risk of 
cardioembolism is unclear. One possibility is that the most important source 
of cardioembolism is atrial fibrillation and some studies have reported a 
positive association between a high intake of fish as well as marine n-3 PUFA 
and risk of atrial fibrillation.98–101 Also, results from the Reduce-it study89 
showed a statistically significant higher risk of atrial fibrillation/atrial flutter 
among participants receiving EPA compared to controls (3.1% vs. 2.1%, 
P=0.004). However, the number of cases with cardioembolism in our study 
was low and those results should be interpreted with caution.  
Our results of the four studies suggest that the associations between n-6 and 
marine n-3 PUFA and ischemic stroke may not be consistent across subtypes 
of ischemic stroke underlining the need to investigate PUFA in relation to the 
individual ischemic stroke subtypes.  
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CHAPTER 8. CONCLUSIONS AND 
PERSPECTIVES 
Our results from the four studies evaluating both dietary intake and content of 
PUFA in adipose tissue suggest: 
• Substitution of dietary LA for SFA, MUFA or glycemic carbohydrates 
may be associated with a lower risk of ischemic stroke and its 
subtypes, apart from stroke due to cardioembolism. 
• Adipose tissue content of LA may be associated with a lower risk of 
ischemic stroke and its subtypes, except for strokes due to 
cardioembolism.  
• Intake of total marine n-3 PUFA, EPA and DHA may be associated 
with a lower risk of large artery atherosclerosis.  
• Adipose tissue content of EPA may be associated with a lower risk of 
total ischemic stroke, large artery atherosclerosis and small-vessel 
occlusion.  
• Adipose tissue content of total marine n-3 PUFA and DHA showed 
inconsistent associations with total ischemic stroke and its subtypes 
except for stroke due to cardioembolism for which a positive 
association was observed.  
• Total and lean fish replacing processed, and unprocessed red meat 
may be associated with a lower risk of large artery atherosclerosis, 
while replacing poultry with total and lean fish may be associated with 
a higher risk of cardioembolism.  
• Fatty fish replacing processed and unprocessed red meat and poultry 
may be associated with a lower risk of large artery atherosclerosis 
and small-vessel occlusion.  
 
The association between substitution of LA and risk of ischemic stroke needs 
further investigation by other prospective studies in order to confirm the lower 
risk of ischemic stroke by increasing the intake of LA at expense of other 
macronutrients found in our study. Although adipose tissue content of LA 
showed a statistically significantly inverse association with the risk of ischemic 
stroke, this result should not be considered definitive and other large 
prospective cohort studies as well as randomized controlled studies are 
needed to confirm or reject our findings.  
Both dietary intake and adipose tissue content of EPA and DHA in relation to 
ischemic stroke deserve further attention. Large prospective cohort studies 
and randomized controlled studies are necessary to confirm or reject the 
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observed inverse association between adipose tissue content of EPA and 
ischemic stroke and its subtypes. Also, experimental studies are needed to 
clarify the biologic mechanisms between EPA and DHA intake and etiology of 
ischemic stroke.  
Evidence from this study suggests that long-term intake of different 
macronutrients is often associated with specific food patterns. Therefore, 
macronutrients should not be investigated isolated and future research should 
also target food patterns. There is especially a need for studies of substitutions 
in relation to ischemic stroke, which is applicable for both macronutrients and 
food items. Furthermore, results from substitution analyses of food items are 
easily translated into dietary guidelines.  
Ischemic stroke is a heterogenous condition and our study results highlight 
the importance of investigating n-6 PUFA, marine n-3 PUFA and fish in 
relation to ischemic stroke subtypes separately. It would be desirable to pool 
data from other prospective cohort studies to increase number of cases for 
the analyses of subtypes of ischemic stroke. In contrary to our hypothesis, 
intake of marine n-3 PUFA was associated with a higher risk of 
cardioembolism. Future directions of research include prospective cohort 
studies with a larger number of cases of stroke due to cardioembolism in order 
to elucidate a potential association.  
Taken together our findings suggest that an increased consumption of foods 
rich in n-6 and marine n-3 PUFA may lower the risk of ischemic stroke 
especially ischemic stroke of atherosclerotic origin, which supports recent 
guidelines.50 Such a diet have also been associated with a lower risk of acute 
coronary syndrome102,103 myocardial infarction104–106 and peripheral arterial 
disease.107,108 Furthermore, the study suggests, that associations depend on 
the macronutrients or food item to be replaced and most likely also on the 
dietary pattern that follows an increased intake of n-6 PUFA and marine n-3 
PUFA.    
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CHAPTER 9. ENGLISH SUMMARY 
Ischemic stroke is a leading cause of death and long-term disability worldwide. 
Though, n-6 and marine n-3 PUFA from the diet have been hypothesized to 
reduce ischemic stroke risk, previous studies have shown inconsistent results. 
The aim of this thesis was to investigate the association between marine n-3 
and n-6 PUFA from dietary intake and content in adipose tissue and the risk 
of ischemic stroke and its subtypes. 
For this thesis, we used the Diet, Cancer and Health cohort which included 
57,053 Danish participants age 50-64 at baseline. All participants filled in a 
food-frequency questionnaire at baseline which was used to investigate 
dietary intake. Furthermore, participants had an adipose tissue biopsy taken 
at baseline and content of fatty acids in adipose tissue (a long-term indicator 
of diet and biological exposure) was analyzed by gas chromatography. 
Potential ischemic stroke cases were found by linkage to the Danish National 
Patient Register. All cases were individually validated and subtyped according 
to the TOAST-classification system.  
During a median follow-up time of 13.5 year 1,879 ischemic strokes occurred. 
In Study I, the association between intake of LA and risk of ischemic stroke 
was investigated by use of substitution models. Hence, a 5% higher intake of 
LA and a concomitant lower intake of SFA, MUFA or glycemic carbohydrates 
was investigated. Results indicated a lower risk of ischemic stroke and 
ischemic stroke subtypes with these substitutions. In Study II, associations 
between adipose tissue content of LA to ischemic stroke and its subtypes was 
investigated and results indicated inverse associations. In Study III, 
association between both dietary intake and adipose tissue content of total 
marine n-3 PUFA, EPA and DHA and risk of ischemic stroke were studied. 
The adipose tissue content of EPA was associated with a lower risk of most 
types of ischemic stroke, while intake of total marine n-3 PUFA, EPA and DHA 
was associated with a lower risk of strokes due to large artery atherosclerosis. 
In Study IV, association between fish intake and ischemic stroke risk was 
investigated using substitution models where 150 g/week (corresponding to a 
portion size) of fish replaced 150 g/week of red meat or poultry. These 
substitutions were not associated with risk of total ischemic stroke however, a 
lower risk of large artery atherosclerosis strokes was observed when fish 
replaced red meat.   
Overall, findings of this thesis indicate that increased intake of foods rich in n-
6 PUFA and marine n-3 PUFA may be of benefit for primary prevention of 
ischemic stroke especially strokes of atherosclerotic origin. 
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CHAPTER 10. DANSK RESUME 
Iskæmisk apopleksi er en hyppig årsag til død og invaliditet på verdensplan. 
Selvom n-6 og marine n-3 fedtsyrer i kosten menes at have en gavnlig effekt 
på risikoen for udvikling af iskæmisk apopleksi, har resultater fra tidligere 
studier været inkonsistente. Målet med denne afhandling var at undersøge 
sammenhængen mellem n-6 og marine n-3 fedtsyrer i kosten og indholdet i 
fedtvæv og risikoen for iskæmisk apopleksi samt undertyper heraf. 
Denne afhandling er baseret på data fra den danske befolkningsundersøgelse 
Kost, kræft og helbred, som inkluderede 57,053 danske deltagere på 50-64 år 
ved rekrutteringstidspunktet. Alle deltagere udfyldte et fødevarefrekvens-
spørgeskema ved studiestart, som blev brugt til at undersøge deltagernes 
vanlige kost. Derudover fik deltagerne ved studiestart taget en fedvævsbiopsi, 
som blev analyseret med gaskromatografi. Potentielle tilfælde af iskæmisk 
apopleksi blev fundet ved kobling med Landspatientregistret. Alle cases blev 
valideret og underopdelt på baggrund af TOAST-klassifikationssystemet.  
I løbet af en median opfølgningstid på 13,5 år udviklede 1879 deltagere 
iskæmisk apopleksi. I Studie I blev associationen mellem indtag af linolsyre 
og risikoen for iskæmisk apopleksi undersøgt ved hjælp af 
substitutionsmodeller, hvorved et øget indtag af linolsyre og et tilsvarende 
mindre indtag af mættet fedt, monoumættet fedt eller glykæmiske kulhydrater 
blev undersøgt. Resultaterne viste en lavere risiko for iskæmisk apopleksi 
samt undertyper af iskæmisk apopleksi ved disse substitutioner. I Studie II 
blev associationen mellem linolsyre i fedtvæv og iskæmisk apopleksi samt 
undertyper undersøgt og resultaterne viste inverse associationer. I Studie III 
blev både indtaget samt koncentrationen af total marine n-3 fedtsyrer i 
fedtvæv og de to undertyper EPA og DHA undersøgt i forhold til risiko for 
iskæmisk apopleksi. Et højt indhold af EPA i fedtvæv var forbundet med en 
lavere risiko for de fleste typer af iskæmisk apopleksi imens indtag af både 
total marine n-3 fedtsyrer, EPA og DHA var forbundet med en lavere risiko for 
storkarsinfarkter. I Studie IV blev sammenhæng mellem indtag af fisk og risiko 
for udvikling af iskæmisk apopleksi undersøgt med substitutionsmodeller, idet 
150 g fisk pr. uge (tilsvarende en normal portionsstørrelse) erstattede 150 g 
rødt kød eller fjerkræ pr. uge. Disse substitutioner var ikke associeret med 
risiko for udvikling af total iskæmisk apopleksi, imidlertid blev en lavere risiko 
for storkarsinfarkter observeret, når fisk blev udbyttet med rødt kød.  
Samlet set indikerer resultaterne i denne afhandling, at et øget indtag af 
fødevarer rige på n-6 og marine n-3 fedtsyrer kan være fordelagtigt i forhold 
til primær forebyggelse af iskæmisk apopleksi, især apopleksi af 
aterosklerotisk oprindelse.   
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